Overexpression of aspartyl-(asparaginyl)-β-hydroxylase in hepatocellular carcinoma is associated with worse surgical outcome

Hepatology

Volumn 52, Issue 1, 2010, Pages 164-173

  Wang, Kui ^a   Liu, Jian ^a   Yan, Zhen Lin ^a   Li, Jun ^a   Shi, Le Hua ^a   Cong, Wen Ming ^a   Xia, Yong ^a   Zou, Qi Fei ^a   Xi, Tao ^a   Shen, Feng ^a   Wang, Hong Yang ^a   Wu, Meng Chao ^a  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA FETOPROTEIN; ASPARTIC ACID BETA HYDROXAMIC ACID; ASPARTYL (ASPARAGINYL) BETA HYDROXYLASE; COMPLEMENTARY DNA; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER PATIENT; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE ASSOCIATION; DNA MICROARRAY; FEMALE; GENE EXPRESSION PROFILING; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; RECURRENCE RISK; SURVIVAL RATE; TREATMENT OUTCOME; TUMOR RECURRENCE; TUMOR VOLUME;

ADOLESCENT; ADULT; AGED; CARCINOMA, HEPATOCELLULAR; FEMALE; HEPATECTOMY; HUMANS; LIVER NEOPLASMS; MIDDLE AGED; MIXED FUNCTION OXYGENASES; NEOPLASM RECURRENCE, LOCAL; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROGNOSIS; PROSPECTIVE STUDIES; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 77954228277     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.23650     Document Type: Article

References (40)

1. El-Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 2007;132:2557-2576. (Pubitemid 46890874)
2. Tang ZY. Hepatocellular carcinoma - cause, treatment and metastasis. World J Gastroenterol 2001;7:445-454. (Pubitemid 32780652)
3. Portolani N, Coniglio A, Ghidoni S, Giovanelli M, Benetti A, Tiberio GA, et al. Early and late recurrence after liver resection for hepatocellular carcinoma: prognostic and therapeutic implications. Ann Surg 2006;243:229-235. (Pubitemid 43185442)
4. Bruix J, Boix L, Sala M, Llovet JM. Focus on hepatocellular carcinoma. Cancer Cell 2004;5:215-219.
5. Poon RT, Fan ST, Lo CM, Liu CL, Wong J. Intrahepatic recurrence after curative resection of hepatocellular carcinoma: long-term results of treatment and prognostic factors. Ann Surg 1999;229:216-222. (Pubitemid 30191795)
6. Sobin LH, Wittekind C. TNM classification of malignant tumors, 6th ed. New York: Wiley-Liss; 2002:81-83.
7. Bruix J, Sherman M, Llovet JM, Beaugrand M, Lencioni R, Andrew K, et al. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL Conference. J Hepatol 2001;35:421-430. (Pubitemid 32844200)
8. Bruix J, Sherman M. Management of hepatocellular carcinoma. HEPATOLOGY 2005;42:1208-1236.
9. Grieco A, Pompili M, Caminiti G, Miele L, Covino M, Alfei B, et al. Prognostic factors for survival in patients with early-intermediate hepatocellular carcinoma undergoing non-surgical therapy: comparison of Okuda, CLIP, and BCLC staging systems in a single Italian centre. Gut 2005;54:411-418.
10. Minagawa M, Ikai I, Matsuyama Y, Yamaoka Y, Makuuchi M. Staging of hepatocellular carcinoma: assessment of the Japanese TNM and AJCC/UICC TNM systems in a cohort of 13,772 patients in Japan. Ann Surg 2007;245:909-922. (Pubitemid 46809293)
11. Iizuka N, Oka M, Yamada-Okabe H, Nishida M, Maeda Y, Mori N, et al. Oligonucleotide microarray for prediction of early intrahepatic recurrence of hepatocellular carcinoma after curative resection. Lancet 2003;361:923-929.
12. Hsu YC, Fu HH, Jeng YM, Lee PH, Yang SD. Proline-directed protein kinase FA is a powerful and independent prognostic predictor for progression and patient survival of hepatocellular carcinoma. J Clin Oncol 2006;24:3780-3788.
13. Ke AW, Shi GM, Zhou J, Wu FZ, Ding ZB, Hu MY, et al. Role of overexpression of CD151 and/or c-Met in predicting prognosis of hepatocellular carcinoma. HEPATOLOGY 2009;49:491-503.
14. Lavaissiere L, Jia S, Nishiyama M, de la Monte S, Stern AM, Wands JR, et al. Overexpression of human aspartyl (asparaginyl) beta-hydroxylase in hepatocellular carcinoma and cholangiocarcinoma. J Clin Invest 1996;98:1313-1323.
15. Ince N, de la Monte SM, Wands JR. Overexpression of human aspartyl (asparaginyl) beta-hydroxylase is associated with malignant transformation. Cancer Res 2000;60:1261-1266.
16. Maeda T, Taguchi K, Aishima S, Shimada M, Hintz D, Larusso N, et al. Clinicopathologic correlates of aspartyl (asparaginyl) beta-hydroxylase overexpression in cholangiocarcinoma. Cancer Detect Prev 2004;28:313-318.
17. Maeda T, Sepe P, Lahousse S, Tamaki S, Enjoji M, Wands JR, et al. Antisense oligodeoxynucleotides directed against aspartyl (asparaginyl) beta-hydroxylase suppress migration of cholangiocarcinoma cells. J Hepatol 2003;38:615-622.
18. Sepe PS, Lahousse SA, Gemelli B, Chang H, Maeda T, Wands JR, et al. Role of the aspartyl-asparaginyl-beta-hydroxylase gene in neuroblastoma cell motility. Lab Inves 2002;82:881-891. (Pubitemid 34761663)
19. Wands JR, Lavaissiere L, Moradpour D, de la Monte S, Mohr L, Nicolau C, et al. Immunological approach to hepatocellular carcinoma. Viral Hepat 1997;4(Suppl. 2):60-74.
20. de la Monte SM, Tamaki S, Cantarini MC, Ince N, Wiedmann M, Carter JJ, et al. Aspartyl-(asparaginyl)-beta-hydroxylase regulates hepatocellular carcinoma invasiveness. J Hepatol 2006;44:971-983.
21. Cantarini MC, de la Monte SM, Pang M, Tong M, D'Errico A, Trevisani F, et al. Aspartyl-asparagyl beta hydroxylase overexpression in human hepatoma is linked to activation of insulin-like growth factor and notch signaling mechanisms. HEPATOLOGY 2006;44:446-457. (Pubitemid 44214884)
22. Xian ZH, Zhang SH, Cong WM, Yan HX, Wang K, Wu MC. Expression of aspartyl beta-hydroxylase and its clinicopathologic significance in hepatocellular carcinoma. Mod Pathol 2006;19:280-286. (Pubitemid 43117613)
23. Poon RT, Fan ST, Ng IO, Lo CM, Liu CL, Wong J. Different risk factors and prognosis for early and late intrahepatic recurrence after resection of hepatocellular carcinoma. Cancer 2000;89:500-507. (Pubitemid 30640096)
24. Edmondson HA, Steiner PE. Primary carcinoma of the liver: a study of 100 cases among 48,900 necropsies. Cancer 1954:7;462-503.
25. Ye QH, Qin LX, Forgues M, He P, Kim JW, Peng AC, et al. Predicting hepatitis B virus-positive metastatic hepatocellular carcinomas using gene expression profiling and supervised machine learning. Nat Med 2003;9:416-423.
26. Shirota Y, Kaneko S, Honda M, Kawai HF, Kobayashi K. Identification of differentially expressed genes in hepatocellular carcinoma with cDNA microarrays. HEPATOLOGY 2001;33:832-840.
27. Hu L, Lau SH, Tzang CH, Wen JM, Wang W, Xie D, et al. Association of Vimentin overexpression and hepatocellular carcinoma metastasis. Oncogene 2004;23:298-302.
28. Llovet JM, di Bisceglie AM, Bruix J, Kramer BS, Lencioni R, Zhu AX, et al. Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst 2008;100:698-711.
29. Gronke RS, VanDusen WJ, Garsky VM, Jacobs JW, Sardana MK, Stern AM, et al. Aspartyl beta-hydroxylase: in vitro hydroxylation of a synthetic peptide based on the structure of the first growth factor-like domain of human factor IX. Proc Natl Acad Sci USA 1989;86:3609-3613.
30. Gronke RS, Welsch DJ, VanDusen WJ, Garsky VM, Sardana MK, Stern AM, et al. Partial purification and characterization of bovine liver aspartyl beta-hydroxylase. J Biol Chem 1990;265:8558-8565. (Pubitemid 20167364)
31. Jia S, VanDusen WJ, Diehl RE, Kohl NE, Dixon RA, Elliston KO, et al. cDNA cloning and expression of bovine aspartyl (asparaginyl) beta-hydroxylase. J Biol Chem 1992;267:14322-14327.
32. Korioth F, Gieffers C, Frey J. Cloning and characterization of the human gene encoding aspartyl beta-hydroxylase. Gene 1994;150:395-399.
33. Dinchuk JE, Henderson NL, Burn TC, Huber R, Ho SP, Link J, et al. Aspartyl beta-hydroxylase (AAH) and an evolutionarily conserved isoform of AAH missing the catalytic domain share exons with junctin. J Biol Chem 2000;275:39543-39554.
34. Jia S, McGinnis K, VanDusen WJ, Burke CJ, Kuo A, Griffin PR, et al. A fully active catalytic domain of bovine aspartyl (asparaginyl) beta-hydroxylase expressed in Escherichia coli: characterization and evidence for the identification of an active-site region in vertebrate alpha-ketoglutarate- dependent dioxygenases. Proc Natl Acad Sci USA 1994;91:7227-7231.
35. Dinchuk JE, Focht RJ, Kelley JA, Henderson NL, Zolotarjova NI, Wynn R, et al. Absence of post-translational aspartyl beta-hydroxylation of epidermal growth factor domains in mice leads to developmental defects and an increased incidence of intestinal neoplasia. J Biol Chem 2002;277:12970-12977.
36. Luu M, Sabo E, de la Monte SM, Greaves W, Wang J, Tavares R, et al. Prognostic value of aspartyl (asparaginyl)-beta-hydroxylase/humbug expression in non-small cell lung carcinoma. Hum Pathol 2009;40:639-644.
37. Palumbo KS, Wands JR, Safran H, King T, Carlson RI, de la Monte SM. Human aspartyl (asparaginyl) beta-hydroxylase monoclonal antibodies: potential biomarkers for pancreatic carcinoma. Pancreas 2002;25:39-44.
38. Talwalkar JA, Gores GJ. Diagnosis and staging of hepatocellular carcinoma. Gastroenterology 2004;127(Suppl.):S126-S132.
39. Bruix J, Llovet JM. Prognostic prediction and treatment strategy in hepatocellular carcinoma. HEPATOLOGY 2002;35:519-524.
40. Torzilli G, Donadon M, Marconi M, Palmisano A, Del-Fabbro D, Spinelli A, et al. Hepatectomy for stage B and stage C hepatocellular carcinoma in the barcelona clinic liver cancer classification: results of a prospective analysis. Arch Surg 2008;143:1082-1090.